Agenda for Day 1 - Monday December 7, 2026
- Samantha Elizondo - Conference Producer, Informa Connect
- Maricel Apuli - Chief Accounting Officer, BridgeBio
Explore how leaders are navigating the complex capital environment of elevated interest rates, selective investor deployment, and scrutiny on cash efficiency and clinical milestones.
Discuss how financing strategies have shifted since the 2020–2021 biotech boom
Explore how companies are balancing clinical advancement, dilution risk, and operational growth
Hear firsthand insights from executives who have navigated delayed IPOs, down rounds, restructurings, and shifting investor expectations
CPE Credits Available: 1.0
- Dominic Piscitelli - Independent Board Member & Audit Committee Chair, Alterome Therapeutics Inc
- Morgan Brown - Chief Financial Officer, Clene Nanomedicine
- Ousmane Caba - Partner, PwC
Understand the critical operational and financial milestones finance teams must prepare for before launch
Explore scenario planning for commercialization timelines, manufacturing readiness, and demand forecasting
Learn how lean finance teams can prepare for launch without overbuilding infrastructure too early
Discuss the biggest commercialization mistakes emerging biotech companies make and how to avoid them
CPE Credits Available: 1.0
- Jake McCracken - Senior Vice President, Finance, Apnimed
- Betsy Gelfand - Senior Vice President Finance, Endeavor BioMedicines
- Christian Nodgaard - Senior Manager, Risk - Life Sciences Advisory, Baker Tilly
Evaluate how emerging biotechs shift capital allocation away from volatile, early-stage internal discovery engines toward de-risked, clinical-stage in-licensed assets.
Analyze best practices for financial and accounting leaders when structuring complex cross-border licensing frameworks, including bio-buck milestones, upfront cash, and equity splits.
Assess the operational and margin benefits of pure-play technology and platform-licensing models that generate highly predictable, recurring revenue.
Formulate strategies to accelerate clinical development timelines by 6–18 months through targeted asset ingestion, driving a faster path-to-exit or commercialization.
CPE Credits Available: 1.0
Learn how finance and FP&A leaders translate operational complexity into compelling investor narratives
Discuss communicating difficult news, delays, revised forecasts, and commercialization pivots
Explore how boards and investors evaluate biotech finance teams in uncertain environments
Hear how companies positioned themselves during challenging fundraising cycles
CPE Credits Available: 1.0
- Will Ater - Chief Financial Officer, Nucleus Biologics
- Priti Barman - Senior Director FP&A, Vera Therapeutics
Understand how commercialization fundamentally changes finance and accounting operations
Explore practical considerations around order-to-cash, stakeholder relationships, reimbursement flows, and distribution
Learn how finance teams should prepare for increased operational complexity post-launch
Discuss common launch readiness gaps in systems, forecasting, and cross-functional alignment
CPE Credits Available: 1.0
- Jim Kihara - SVP, Finance/Chief Accounting Officer, Acadia Pharmaceuticals
- Jake McCracken - Senior Vice President, Finance, Apnimed
Strategic Capital Allocation: Extending Runway Without Stalling Growth
Explore frameworks for prioritizing spend across clinical operations, commercialization readiness, and infrastructure
Discuss how companies determine whether to build internally versus outsource
Examine how finance leaders evaluate “must-have” versus “nice-to-have” operational investments
Learn approaches for aligning runway with clinical and regulatory inflection points
CPE Credits Available: 1.0
- Maggie Berkeley - Principal, Risk Consulting, RSM US LLP
- Adam Lohr - Partner, Life Sciences Senior Analyst, RSM US LLP
Discuss the lack of reliable benchmarking data across biotech finance operations
Explore how companies evaluate launch costs, commercial buildout expenses, and trial spending assumptions
Learn how finance leaders leverage internal data, external advisors, and peer networks to inform decision-making
Examine how benchmarking changes across development stages and therapeutic areas
CPE Credits Available: 1.0
- Priti Barman - Senior Director FP&A, Vera Therapeutics
- Jill Broadfoot - Former CFO, aTyr Pharma
- Nancy Lemus - Director of Finance & Operations, BPS Bioscience
Small group discussions focused on:
Launch readiness timelines
Demand forecasting risk
Capital allocation decisions
Outsourcing versus internal build
Commercial finance team design
IPO versus M&A readiness
Lessons from failed launches and restructurings
CPE Credits Available: 1.0
- Maricel Apuli - Chief Accounting Officer, BridgeBio
- Christine Mikail - President & CFO, Neurogene Inc.
